Awardees HelpWear and Us2.ai recognized for their novel ideas to harness the Internet of Things (IoT) and Artificial Intelligence (AI) with the aim to transform Atrial fibrillation (AFIB) patient care.
SHANGHAI, Sept. 24, 2021 /PRNewswire/ — Johnson & Johnson Innovation LLC together with Johnson & Johnson Medical Shanghai Ltd. today at AmCham China’s Technology and Innovation Summit named HelpWear and Us2.ai as awardees of the Digital Technologies of Tomorrow QuickFire Challenge. The Challenge aimed to support innovators working on promising medical device technologies such as Artificial Intelligence, 3D-printing, the Internet of Things, and 5G in diagnostics, perioperative treatment solutions, and emerging and transformative technologies.
- HelpWear: Toronto-based HelpWear builds a continuous clinical-grade ECG monitoring system capable of providing near-real-time data to care providers enabling timely medical interventions and better management of patients follow arrhythmias such as atrial fibrillation.
- Us2.ai: Singapore-based Us2.ai aims to automate the fight against heart disease, using machine learning techniques to enable fast interpretation of echocardiography images of the highest quality.
They will receive a combined total of $100,000 in grant funding; one year of residency at JLABS @ Shanghai, including a workstation and access to the Johnson & Johnson Innovation – JLABS ecosystem; and mentorship from experts across the Johnson & Johnson Family of Companies.
“Digital technologies are creating unprecedented opportunity to reimagine how care is accessed, delivered, managed and experienced. At Johnson & Johnson Innovation, we aim to build and scale user-centered digital health solutions and business models in partnership or collaboration with technology companies whose capabilities complement our scientific expertise,” said Sharon Chan1, Head of JLABS @ Shanghai. “We are excited to work closely with these promising awardees with the aim to accelerate ideas and deliver potential breakthrough solutions for the patients and consumers of tomorrow.”
The challenge invited applications from entrepreneurs and innovators working on novel technologies specifically related to:
- AFIB: How can we leverage digital technologies with the aim to identify patients and refer them to the appropriate physicians? How can we trace patients for remission after treatment?
- Neurovascular Treatments: How can we detect signs/ risks of stroke for early treatment?
- General and orthopedic surgery, including distant operating stage support and AI-enabled procedure planning: How can we drive more effective potential perioperative solutions (including pre-, intra- and post-surgery) with emerging technologies? How can we apply innovative, untraditional material to orthopedics surgery?
The awardees were evaluated based on criteria including potential impact, the uniqueness of their potential solution and competitive landscape, clarity of plan, feasibility and potential to commercialize within twelve months, team credibility & capabilities, and the potential impact on Chinese ecosystem.
As part of their efforts to help deeply transform patient experiences along their treatment pathways, Johnson and Johnson Medical Shanghai Ltd. is widely seeking collaborations with health technology pioneers, including both companies and organizations, to help catalyze innovative potential solutions for the healthcare industry in China and beyond.
Johnson & Johnson Innovation has developed the QuickFire Challenge platform with the aim to help enable potential groundbreaking science and health solutions by encouraging students, entrepreneurs, researchers and start-up companies to tackle some of the world’s most challenging problems in healthcare. Through our diverse regional team in Shanghai, our science and technology experts aim to help life science startups thrive and fuel the global life science ecosystem through flexible, customized partnership models and collaborations; early-stage incubation, startup services and mentorship; and strategic venture capital investments.
For more information about the QuickFire Challenges, please visit: https://jlabs.jnjinnovation.com/quickfire-challenges.
About Johnson & Johnson Innovation
Johnson & Johnson Innovation LLC works across the pharmaceutical, medical device and consumer health sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at www.jnjinnovation.com.
About Johnson & Johnson Medical Devices
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to the award announcement of the Seoul Innovation QuickFire Challenge on Smart Surgery. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Innovation LLC, Johnson & Johnson Medical Korea Ltd and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of clinical success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in the company’s most recently filed Quarterly Report on Form 10-Q, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson Innovation LLC, Johnson Medical Korea Ltd and/or Johnson & Johnson do not undertake to update any forward-looking statement as a result of new information or future events or developments.
1 Sharon Chan is employed by Johnson & Johnson (Hong Kong) Limited